Cytokinetics vs Fortress Biotech
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $63.3m for Fortress Biotech (1.4 times as much). Cytokinetics grew faster (376.6% against 9.7%). Fortress Biotech kept more of each dollar of sales as profit: a net margin of 10.8% against -891.6%.
| Latest fiscal year | CytokineticsCYTK, 2025 | Fortress BiotechFBIO, 2025 |
|---|---|---|
| Revenue | $88.0m | $63.3m |
| Revenue growth | 376.6% | 9.7% |
| Net income | −$785m | $6.8m |
| Operating margin | -695.4% | — |
| Net margin | -891.6% | 10.8% |
| Return on equity | — | 18.8% |
| Free cash flow | −$535m | −$65.8m |
| Cash | $123m | $79.4m |
| Total debt | $999m | $54.5m |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | 0.8% |
| Share buybacks | — | — |
| Employees | 673 | 78 |
| Market value | $7.69bn | $64.5m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 85 sales | 0 buys, 0 sales |